

# Chronic kidney disease and coenzyme Q10 supplementation

Among the potential causes of chronic kidney disease (CKD), mitochondrial respiratory chain (MRC) dysfunction, oxidative stress and inflammation have been implicated as contributor factors to the pathogenesis of this disorder. It is thought that CoQ10 supplementation may offer some therapeutic potential in the treatment of patients with CKD, since CoQ10 has a key role in normal MRC function, as well as having antioxidant and anti-inflammatory action. This article will outline the current knowledge on the use of CoQ10 in the treatment of CKD

■ chronic kidney disease ■ coenzyme Q10 ■ haemodialysis ■ cardiovascular disease

**C**hronic kidney disease (CKD) is defined as a permanent loss of kidney function, characterised by a reduced ability of the kidneys to excrete waste products from metabolic processes, resulting in the build-up of uremic toxins in the blood (Barreto et al, 2014). CKD is classified into five stages, depending on the glomerular filtration rate (GFR); this is the rate of filtration across the glomerular filtration barrier, measured in units of ml/min/1.73m<sup>2</sup>, with normal values typically in the range of 90–120. Patients with severe CKD (stage 5) are typically treated by dialysis to remove uremic toxins, correct electrolyte and acid base imbalance and, in patients with reduced urine output, regulate body water (Dhondup and Qian, 2017). It is estimated that the prevalence of CKD in the general UK population is approximately 10% (Public Health England, 2014). There are a number of causes of CKD, with hypertension and diabetes being among the most prominent (Romagnani et al, 2017).

CoQ10 is a lipophilic molecule, consisting of a benzoquinone nucleus and an isoprenoid side chain (*Figure 1*), which plays a key role in cellular energy generation within the mitochondrial respiratory chain (MRC) (*Figure 2*), as well as

having an important antioxidant and anti-inflammatory action (Fan et al, 2017). CoQ10 occurs within the body in two very closely related chemical forms: an oxidised form (ubiquinone) (*Figure 1a*) and a reduced form (ubiquinol) (*Figure 1b*).

The chemical structure of CoQ10 is relatively complex, and ubiquinol differs from ubiquinone only by the addition of an extra two hydrogen atoms. The antioxidant activity of CoQ10 is provided by ubiquinol (Hargreaves, 2014). The reductive regeneration of ubiquinol is vital to maintain its antioxidant function. The MRC ensures that the inner mitochondrial membrane CoQ10 pool is kept in its fully reduced ubiquinol state (Aberg et al, 1992). The enzyme named electron transfer flavoprotein-ubiquinone oxidoreductase (ETF<sub>OH</sub>) also contributes to the reduction of the CoQ10 pool within the inner mitochondrial membrane (Gempel et al, 2007). CoQ10 is reduced to ubiquinol on the outer surface of the inner mitochondrial membrane by the enzyme dihydroorotate dehydrogenase during pyrimidine synthesis (Turunen et al, 2004). In the plasma and endomembranes (membranes of the different organelles within the cytoplasm of the cell), there are at least four enzymes that are known to maintain CoQ10 in its ubiquinol form. These enzymes are NADH cytochrome b5 reductase, NADH/NADPH oxidoreductase, NADPH coenzyme Q reductase (NQO1) and dihydroorotate dehydrogenase (Takahashi et al, 1996; Villalba and Navas, 2000).

However, in addition to their antioxidant potential, the therapeutic efficacy of CoQ10 and its synthetic analogues, such as idebenone in the treatment of MRC disorders, is also thought to rely on their ability to enhance electron flow in the MRC (Hargreaves, 2014; Neerghen et al, 2017).

## Iain Hargreaves

Senior Lecturer, National Hospital for Neurology and Neurosurgery, London and Liverpool John Moores University

Email: i.p.hargreaves@ljamu.ac.uk

## David Mantle

Medical Adviser, Pharma, Morpeth, Northumberland

## David Milford


Consultant Nephrologist, Birmingham Children's Hospital

## Mitochondrial dysfunction in CKD


The waste products of metabolism, uremic toxins, are normally excreted in the urine, but can accumulate in the body as a result of CKD and have been reported to cause impairment of MRC function (Mutsaers et al, 2013; Granata et al, 2015) (Figure 2). This can result from inhibition of MRC complex II (succinate: ubiquinol reductase) and/or complex IV (cytochrome c oxidase) activities (Granata et al, 2009; 2015). Furthermore, in vitro studies have indicated that the CKD reported in patients with primary hyperaldosteronism may result from aldosterone-induced mitochondrial dysfunction in the podocytes. The mitochondrial dysfunction appears to result from an aldosterone-induced decrease in mitochondrial DNA (mtDNA) copy number as a consequence of increased mitochondrial reactive oxygen species (ROS) generation (Su et al, 2013).

Interestingly, a decrease in mtDNA has also been reported in Finnish type congenital nephrotic syndrome (Solin et al, 2000). Once impaired, the MRC becomes a major source of ROS, which can result in oxidative stress once cellular antioxidant defences have been overwhelmed (Stepien et al, 2017), and has been reported in animal models of CKD (Owada et al, 2010). The major sites of ROS generation within the MRC are at complex I and complex III (Quinlan et al, 2013). Oxidative stress can also result in inflammation, which can mediate a host of chronic diseases (Stepien et al, 2017; Delacruz and Kang, 2018; Grazioli and Pugin, 2018; Meyer et al, 2018). In addition, the levels of a number of pro-inflammatory cytokines considered to be uremic toxins increase in CKD, contributing to the pathophysiology of this condition (Castillo-Rodriguez et al, 2017).

The release of mitochondria-derived damage-associated molecular patterns (DAMPs) as the result of mitochondrial dysfunction may also contribute to the inflammatory response by interacting with receptors similar to those involved in the pathogen-associated immune response (Picca et al, 2017). Furthermore, a study in a mouse model of Parkinson's disease has indicated that mitochondrial dysfunction is able to multiply the inflammasome signalling pathway-driven proinflammatory cascade in microglia (Sarkar et al, 2017). Moreover, inflammation has also been associated with the inhibition of MRC enzyme activity, as illustrated in the autoimmune inflammatory disorder multiple sclerosis (Hargreaves et al, 2018), as well as the systemic inflammatory response syndrome in sepsis (Stepien et al, 2017).



**Figure 1: Structures of Coenzyme Q10 (CoQ10;A) and ubiquinol (B).**



**Figure 2: Diagram of the mitochondrial respiratory chain (MRC) and complex V illustrating proton (H<sup>+</sup>) movement during oxidative phosphorylation. Q: Coenzyme Q10**

**Cyt C: Cytochrome c**

MRC dysfunction, oxidative stress and inflammation can interact in a mutually reinforcing manner, with deleterious effects on the functioning of all tissues, but particularly those with high energy demands, such as the heart and kidneys. Therefore, in view of the association between CKD, MRC dysfunction, oxidative stress and inflammation, it is the purpose of this article to discuss evidence for the potential role of CoQ10 in the treatment of patients with CKD.

## CoQ10

CoQ10 plays a key role in the biochemical process that supplies all cells with the energy required for their normal functioning. Specifically,

CoQ10 serves as an electron carrier in the MRC, transferring electrons derived from complex I (NADH:ubiquinone reductase) and complex II to complex III, allowing a continuous passage of electrons within the chain which is required for the process of oxidative phosphorylation and consequent ATP production (Hargreaves, 2003) (*Figure 2*). In its reduced ubiquinol form, CoQ10 also functions as a potent lipid-soluble antioxidant that is considered more efficient than vitamin E (Frei et al, 1990). It has been suggested that ubiquinol acts earlier in the prevention of lipid peroxidation than vitamin E (Ernster and Forsmark-Andree, 1993), and is also able to regenerate the active  $\alpha$ -tocopherol form of the vitamin from the  $\alpha$ -tocopheroxyl radical. Ubiquinol is able to inhibit lipid peroxidation (Ernster et al, 1992; Ernster and Dallner, 1995), and is present in the membranes of all other subcellular organelles, such as microsomes, lysosomes and the Golgi apparatus (Crane, 2001; Turunen et al, 2004; Littarru et al, 2007).

In the plasma membrane, ubiquinol can prevent lipid peroxidation by itself or by reducing the antioxidants  $\alpha$ -tocopherol and vitamin C (Navas et al, 2007). Ubiquinol also plays an important role as an antioxidant protecting circulatory lipoproteins from free radical induced oxidative damage (Romagnoli et al, 1994; Alleva et al, 1995). It is important to stress that ROS can serve as signalling molecules regulating important biological and physiological functions within the cell (Finkel, 2011). However, excessive production of ROS will overwhelm the intracellular antioxidant defenses causing oxidative damage to lipids, proteins and DNA (Cross et al, 1987; Matsuzaki et al, 2009). In addition, gene expression profiling has shown that CoQ10 influences the expression of several hundred genes (Gutierrez-Mariscal et al, 2018). In particular, studies in cell culture, animal models and human subjects have shown that CoQ10 can directly regulate gene expression relevant to inflammation and fat metabolism (Schmelzer et al, 2008). At least 13 genes are involved in the biosynthesis of CoQ10 itself, and mutations in 10 of these genes have been reported to result in primary CoQ10 deficiency (Awad et al, 2018; Yubero et al, 2018).

An adequate supply of CoQ10 is essential for the normal functioning of mitochondria. Most of the daily CoQ10 requirement is synthesised within the body, with a small amount being obtained from dietary sources (Weber et al, 1997). CoQ10 biosynthesis is a multistage process, with the benzoquinone nucleus being derived from tyrosine and the isoprenoid side chain (*Figure 1*) being derived from acetyl-CoA via the mevalonate pathway (Turunen et al, 2004). Following the condensation of

the side chain and benzoquinone nucleus, the final modification of the benzoquinone nucleus to form CoQ10 occurs within the mitochondria (Turunen et al, 2004; Navas et al, 2007). CoQ10 is present within all cellular membranes, including the plasma membrane; however, it is found in the highest amounts within the outer and inner membranes of the mitochondria, lysosomes and golgi body, where it serves as a respiratory chain redox carrier, proton transporter and antioxidant (Turunen et al, 2004).

As people age, the body becomes less efficient at producing its own supply of CoQ10, with levels in cardiac tissue at age 65 being less than 50% of those at age 25 (Kalén et al, 1989); this is why people may choose to take supplemental CoQ10 to correct this potential deficit. An important factor to consider that may influence the efficacy of CoQ10 supplementation is the type of CoQ10 formulation employed, as this will influence the bioavailability of CoQ10 absorbed from the digestive tract into the bloodstream. When supplemental CoQ10 is first produced (via a yeast fermentation process), it is obtained in the form of crystals that cannot be absorbed from the digestive tract (Mantle, 2015). It is essential that these crystals are dispersed into single CoQ10 molecules (and remain dispersed during the product shelf-life) for optimum bioavailability, but manufacturers vary greatly in their ability to achieve this goal. In view of their superior absorption, the use of gel- and oil-based formulations of CoQ10 have been recommended in preference to tablets in the treatment of patients with mitochondrial disease (Weis et al, 1994). Recently, a study by Martinefski et al (2017) reported that soft gel formulations improved the bioavailability of CoQ10 with respect to solid formulations.

At present, there is considerable debate on whether formulations of ubiquinol—CoQ10 in its fully reduced form (Hargreaves, 2003)—have a better absorption from the gastrointestinal (GI) tract than those of CoQ10. It is reported that the absorption of ubiquinol by the GI tract is 3–4 times greater than that of CoQ10 (Bhagavan and Chopra, 2007; Garcia-Corzo et al, 2014). However, upon absorption from the GI tract, CoQ10 undergoes reduction to ubiquinol; therefore, the reported superior bioavailability of ubiquinol formulations to that of CoQ10 may be attributable to the matrix in which the ubiquinol is encapsulated. Furthermore, at present there are limited data available from clinical studies, and there are no indications of dosage compatibility (Desbats et al, 2015).

### CoQ10 and kidney function in CKD

Plasma CoQ10 levels have been reported to be significantly lower in CKD patients (with or without

haemodialysis), compared with normal controls (Triolo et al, 1994; Macunluoglu et al, 2014; Yeung et al, 2015). The cause of this deficit in serum CoQ10 levels is as yet uncertain; however, it may be associated with the increased oxidative stress reported in CKD (Oberg et al, 2004). The oxidative stress in CKD, as a result of either MRC dysfunction or from other sources (Galli et al, 2001), may cause an increased degradation of CoQ10 (Miranda et al, 1999). Furthermore, it has been suggested that the enzymes involved in CoQ10 biosynthesis may exist in a super enzyme complex, which is located in mitochondria in close proximity to MRC in the inner mitochondrial membrane (Marbois et al, 2005; Ashraf et al, 2013). A deficiency in MRC enzyme activity may therefore impact upon the structural formation or function of the CoQ10 super enzyme complex, possibly as the result of increased ROS generation which has been associated with MRC enzyme dysfunction (Quinlan et al, 2013), causing oxidative-stress-induced impairment of CoQ10 biosynthetic enzymes, which may therefore compromise CoQ10 biosynthesis (Yubero et al, 2016).

There is some evidence that CoQ10 supplementation may improve renal function and reduce the need for dialysis in patients with CKD. In a randomised controlled study (Singh et al, 2003), 97 CKD patients were given supplementary CoQ10 (3 x 100 mg daily for 3 months), or a placebo. There was a significant improvement in markers of renal function (e.g. serum creatinine) in CoQ10-supplemented patients compared with those who received a placebo, in both dialysed and non-dialysed patients. In particular, the number of patients requiring dialysis in the CoQ10 treated group decreased from 21 to 12, while remaining unchanged at 24 in the placebo group. In an animal model of CKD, the reduced form of CoQ10—ubiquinol—was found to decrease kidney superoxide levels, as well ameliorating renal dysfunction (Ishikawa et al, 2011).

Decreased CoQ10 levels may be a particular issue in CKD patients prescribed the cholesterol-lowering drugs statins, since some studies have reported a deficit in CoQ10 status in association with this pharmacotherapy in a subset of patients. It has been suggested that these patients may have some form of underlying mitochondrial disease and therefore may be more susceptible to the adverse effects of statin therapy (Hargreaves et al, 2016). Statins are potent inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase, the rate-limiting enzyme in cholesterol biosynthesis. Statins can also inhibit the body's production of coenzyme Q10 (CoQ10), which is synthesised via the same biochemical pathway as cholesterol. The statin-induced reduction in CoQ10

levels has been well documented in both animal models and clinical studies. Adverse effects in some patients (particularly muscle pain) resulting from statin use has been rationalised in terms of CoQ10 depletion; supplementation with CoQ10 is effective in ameliorating statin-induced muscle pain (Littlefield et al, 2014; Skarlovnik et al, 2014; Qu et al, 2018).

### CoQ10, oxidative stress and haemodialysis

Although haemodialysis is essential for removing uremic toxins, it is a consequence of the procedure that individuals are subject to additional oxidative stress (a result of neutrophil exposure to the synthetic material comprising the dialyser membrane), in addition to the oxidative stress associated with CKD. A number of clinical studies have reported that supplementation with CoQ10 significantly improves outcomes in haemodialysis patients by reducing markers of oxidative stress and inflammation. In a randomised controlled trial, Zahed et al (2016) reported that CoQ10 supplementation (100 mg/day for 3 months) in end-stage CKD patients undergoing haemodialysis significantly reduced serum levels of the inflammatory marker C-reactive protein. An open label dose escalation study by Yeung et al (2015) showed supplementation with CoQ10 over the range 300–1800 mg/day for 14 days to be safe and well tolerated, significantly reducing plasma levels of the oxidative stress marker isofuran. It was suggested by Yeung et al (2015) that the decrease in oxidative stress observed in patients following CoQ10 treatment may have resulted from the ability of this molecule to improve mitochondrial function, rather than as a consequence of any systemic antioxidant effect.

### CoQ10 and cardiovascular disease in CKD patients

Patients with CKD are at high risk of developing cardiovascular disease, with a 10–20 fold increased risk of cardiovascular mortality compared with non-CKD individuals. In particular, there is a high prevalence of atrial fibrillation in CKD patients (Huang et al, 2016). Overall, approximately 50% of deaths in CKD patients result from cardiovascular disease, rather than as a direct consequence of kidney failure. Conversely, cardiovascular disease can cause CKD, leading to a cycle in which each disorder exacerbates the other. Thus, treatment of CKD can reduce the incidence of cardiovascular disease, and treatment of cardiovascular disease can reduce further deterioration in renal function.

In this regard, a randomised controlled clinical trial (Q-SYMBIO) of patients with chronic heart failure (in whom CoQ10 levels are depleted), supplementation with CoQ10 (Bio-Quinone

Q10 200 mg/day for 2 years) reduced the risk of cardiovascular related mortality by 43% (Mortensen et al, 2014). Similarly, the KISEL-10 study was a randomised controlled clinical trial, involving long-term (5 year) supplementation of a normal older population with coenzyme Q10 (Bio-Quinone Q10 200mg/day) and selenium (SelenoPrecise, 200 mcg/day). Cardiovascular mortality was significantly reduced in supplemented individuals by 53%; in addition, biochemical markers of systemic oxidative stress and inflammation were significantly reduced, and heart function, hospitalisation frequency and quality of life significantly improved (Alehagen et al, 2013; Alehagen et al, 2015a; 2015b; Johansson et al, 2015). A randomised controlled trial in haemodialysis patients reported that supplementation with CoQ10 (1200 mg/day for 4 months) resulted in a significant decrease in the level of plasma F2-isoprostanes, a bio-marker of oxidative stress (Rivara et al, 2017). To date, no randomised controlled trials have been carried out to determine clinical outcome for reducing cardiovascular risk in CKD patients.

The ratio of plasma CoQ10 versus LDL cholesterol+ VLDL cholesterol, considered to be more important in atherosclerosis prevention than the ratio of HDL:LDL cholesterol (Tomasetti et al, 1999), was significantly lower in CKD patients (with or without dialysis) compared with controls.

Epicardial fat thickness, a new risk factor for cardiovascular disease, was found to be significantly greater in CKD patients undergoing haemodialysis compared with controls, and correlated with reduced plasma CoQ10 levels (Lippa et al, 2000). Similarly, coronary flow reserve, an indicator of atherosclerosis, was reported to be significantly lower in haemodialysis patients, correlating inversely with serum CoQ10 levels (Macunluoglu et al, 2014).

### CKD and MRC disorders

CKD can also be a clinical presentation of primary MRC disorders that can result in either tubular defects and/or glomerulopathies, the latter being the more common clinical presentation (Emma et al, 2016). In view of the high metabolic demand of renal tubular cells, they are very susceptible to deficits in mitochondrial energy metabolism and, consequently, renal tubular defects are frequently reported in patients with MRC disorders (Emma and Salviati, 2017). Amongst the tubular disorders, Fanconi Syndrome, which is a disorder of inadequate reabsorption in the proximal renal tubules of the kidney, has often been reported as one of the clinical presentations from a variety of mitochondrial diseases (Emma and Salviati, 2017).

In addition to renal tubular disorders, glomerulopathies have also been reported amongst

the clinical sequelae of patients presenting with mitochondrial disease. Although renal involvement is rare in patients with MELAS mitochondrial encephalopathy lactic acidosis and stroke-like episodes (MELAS), patients harbouring the 3243 A>G mtDNA point mutation have been reported to present with renal disease as the result of glomerular dysfunction (Hall et al, 2015). Although no assessment of the CoQ10 status of MELAS patients was undertaken in the study by Hall et al (2015), previous studies have reported evidence of a deficit in CoQ10 status in patients with various mtDNA disorders (Hargreaves et al, 2014). Prompt diagnosis of a deficit in CoQ10 status is imperative, since a dramatic improvement in the clinical status of such patients has been reported following CoQ10 supplementation (Montini et al, 2008).

Inherited defects in CoQ10 biosynthesis have also been associated with glomerular disease, with the urinary space occupied by swollen podocytes with extensive foot process fusion and containing high numbers of dysmorphic mitochondria (Emma and Salviati, 2017). Defects in CoQ10 metabolism appear to specifically impair podocyte function and should be considered among the other causes of a podocytopathy (Singh et al, 2015). At present, it is uncertain why podocyte function is so sensitive to a deficit in CoQ10 status. However, in view of their dependence on oxidative phosphorylation for energy generation together with high mitochondrial enrichment, a deficit in CoQ10 status would be expected to impair MRC function as well as compromising cellular antioxidant status (Hargreaves, 2003).

In humans, at least 13 genes are thought to be involved in the biosynthesis of CoQ10, and mutations in 10 of these genes have been identified to date (Doimo et al, 2014; Awad et al, 2018; Yubero et al, 2018). Renal dysfunction in association with CoQ10 deficiency was first reported by Rotig et al (2000) in three siblings with severe encephalomyopathy and steroid resistant nephrotic syndrome. A further two siblings with steroid resistant nephrotic syndrome and CoQ10 deficiency were reported (Salviati et al, 2005). Subsequent investigations identified mutations in the COQ2 gene (which encodes 4-hydroxybenzoate polyprenyl transferase) of these two siblings, making them the first patients with a primary CoQ10 deficiency to achieve a genetic diagnosis (Quinzii et al, 2006).

Subsequent to the above, mutations in PDSSI, PDSS2, CoQ6 and ADCK 44 genes have been associated with steroid resistant nephrotic syndrome and CoQ10 deficiency (Emma and Salviati, 2017). However, in contrast to the other mutations which present with both neurological and renal

dysfunction, steroid resistant nephrotic syndrome appears to be the sole clinical presentation of patients with mutations in ADCK 44 gene. The ADCK 44 gene encodes for a putative kinase which is thought to have a regulatory function within the CoQ10 biosynthetic pathway, possibly by interaction with the enzymes of the CoQ10 super-complex (Ashraf et al, 2013).

Patients who develop steroid resistant nephrotic syndrome as a result of a CoQ10 deficiency appear to respond well to high dose CoQ10 supplementation, if treatment is initiated early in the disease course, with progressive recovery of renal function and decreased proteinuria being reported (Diomedi-Cammasei et al, 2007; Heeringa et al, 2011; Cao et al, 2017). Unfortunately, CoQ10 supplementation was reported to be unsuccessful in inducing recovery of renal function once chronic renal failure had developed (Montini et al, 2008). Supplementation with CoQ10 at doses of 30–50 mg/kg/day have been recommended (Emma and Salviati, 2017). However, at present there is no consensus on the appropriate dosage that should be used to treat these disorders. In order to exploit the window of opportunity, whereby organ dysfunction may be amenable to CoQ10 treatment, supplementation at birth has been recommended for siblings of patients with confirmed CoQ10 deficiencies (Desbats et al, 2015).

### Clinical monitoring of CoQ10 status

Clinical monitoring of CoQ10 status is generally based on plasma determinations; however the level of circulatory CoQ10 is influenced by both diet and circulatory lipoprotein status (Yubero et al, 2014). There is uncertainty as to whether plasma CoQ10 status reflects that of other tissues and is an appropriate surrogate for use in this assessment (Yubero et al, 2014). Skeletal muscle is the tissue of choice for this determination; however, in view of the possibility that there may be tissue-specific isoenzymes in the CoQ10 biosynthetic pathway, or that a CoQ10 deficiency may be localised to a single organ, other surrogates may be more appropriate to assess renal CoQ10 status (Yubero et al, 2014). At present, there are no studies that have assessed the CoQ10 status of normal human renal tissue, due to the invasive nature of a kidney biopsy. However, urinary tract CoQ10 analysis could be an appropriate approach for assessing kidney CoQ10 status, and may help fulfil the critical need for less invasive procedures to determine tissue CoQ10 status. Recently, a new methodology for the measurement of CoQ10 in urine has been standardised, including the establishment of reference values for a paediatric

### Key points

- Mitochondrial dysfunction, oxidative stress and inflammation have been implicated in the pathogenesis of chronic kidney disease (CKD)
- Depletion of Coenzyme Q10 (CoQ10) levels, which has an important role in mitochondrial cellular energy generation and as an antioxidant/anti-inflammatory, has been demonstrated in CKD patients
- Depletion of CoQ10 in CKD can result primarily from genetic defects in the CoQ10 biosynthesis pathway, or secondarily from oxidative stress linked to the CKD disease process (e.g. uremic toxin accumulation) and/or haemodialysis
- Randomised controlled clinical trials have shown oral supplementation with CoQ10 can improve renal function and reduce the need for dialysis in CKD patients, or improve the clinical status in patients undergoing dialysis
- Supplementation of CoQ10 at an early stage is of particular importance in kidney disease linked to genetic mutations in the biosynthetic pathway, since patients may show a dramatic clinical improvement if CoQ10 deficiency is corrected as soon as practicable

### CPD reflective questions

- Consider how you might apply what you have learned from this article to potentially benefit patients with chronic kidney disease (CKD) in your care
- Consider how you might use information from this article to inform other healthcare professionals who may be unfamiliar with the background to CoQ10
- In young patients with renal disease, consider how you might identify whether they were suffering from an inherited form of CoQ10 deficiency

control population (Yubero et al, 2015). This new evaluation of urinary tract CoQ10 is a non-invasive procedure that might be useful for estimating CoQ10 kidney status for diagnosis and especially for CoQ10 treatment monitoring.

### Conclusion

In conclusion, this article has reviewed the published literature providing a rationale for the role of CoQ10 in the pathogenesis of CKD. Several clinical studies (both randomised controlled and open) have been identified that indicated oral supplementation with CoQ10 in CKD patients could improve kidney function in both non-dialysed and dialysed patients. Similarly, clinical studies have demonstrated that oral supplementation with CoQ10 is effective, when administered sufficiently early, in preventing renal dysfunction manifesting in patients with genetically related primary CoQ10 deficiency. In addition to its role in renal function, it has been suggested that supplementation with CoQ10 may be effective in reducing the risk of developing cardiovascular disease in CKD patients. However, to date, no randomised controlled trials have been carried out to investigate the efficacy of CoQ10 supplementation on clinical outcome for cardiovascular disease in CKD patients, and this is a promising area for future research. **JKC**

*Conflicts of interest:* David Mantle is Medical Adviser to Pharma Nord UK

## References

- Aberg F, Appelkvist EL, Dallner G, Ernster L. Distribution and redox state of ubiquinones in rat and human tissues. *Arch Biochem Biophys.* 1992; 295(2):230–234
- Alehagen U, Johansson P, Björnstedt M et al. Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. *Int J Cardiol.* 2013; 167(5):1860–1866. <https://doi.org/10.1016/j.ijcard.2012.04.156>
- Alehagen U, Lindahl TL, Aaseth J et al. Levels of sP-selectin and hs-CRP decrease with dietary intervention with selenium and coenzyme Q10 combined: a secondary analysis of a randomized clinical trial. *PLOS ONE.* 2015a; 10(9):e0137680. <https://doi.org/10.1371/journal.pone.0137680>
- Alehagen U, Aaseth J, Johansson P. Less increase of copeptin and MR-proADM due to intervention with selenium and coenzyme Q10 combined: results from a 4-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens: less increase of copeptin and MR-proADM. *BioFactors.* 2015b; 41(6):443–452. <https://doi.org/10.1002/biof.1245>
- Alleva R, Tomasetti M, Battino M et al. The roles of coenzyme Q10 and vitamin E on the peroxidation of human low density lipoprotein subfractions. *Proc Natl Acad Sci USA.* 1995; 92(20):9388–9391
- Ashraf S, Gee HY, Woerner S et al. ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption. *J Clin Investig.* 2013; 123(12):5179–5189. <https://doi.org/10.1172/jci69000>
- Awad AM, Bradley MC, Fernández-del-Río L et al. Coenzyme Q10 deficiencies: pathways in yeast and humans. *Essays Biochem.* 2018; 62(3):361–376. <https://doi.org/10.1042/ebc20170106>
- Barreto FC, Stinghen AEM, Oliveira RB de et al. The quest for a better understanding of chronic kidney disease complications: an update on uremic toxins. *Jornal Brasileiro de Nefrologia.* 2014; 36(2):221–235. <https://doi.org/10.5935/0101-2800.20140033>
- Bhagavan HN, Chopra RK. Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. *Mitochondrion.* 2007; 7:S78–S88. <https://doi.org/10.1016/j.mito.2007.03.003>
- Cao Q, Li GM, Xu H et al. [Coenzyme Q(10) treatment for one child with COQ6 gene mutation induced nephrotic syndrome and literature review]. *Zhonghua Er Ke Za Zhi.* 2017; 55(2):135–138. <https://doi.org/10.3760/cma.j.isn.0578-1310.2017.02.016>
- Castillo-Rodríguez E, Fernandez-Prado R, Martin-Cleary C et al. Kidney injury marker 1 and neutrophil gelatinase-associated lipocalin in chronic kidney disease. *Nephron.* 2017; 136(4):263–267. <https://doi.org/10.1159/000447649>
- Crane FL. Biochemical functions of coenzyme Q10. *J Am Coll Nutr.* 2001; 20(6):591–598
- Cross CE, Halliwell B, Borish ET et al. Oxygen radicals and human disease. *Ann Intern Med.* 1987; 107(4):526–545
- Dela Cruz CS, Kang M-J. Mitochondrial dysfunction and damage associated molecular patterns (DAMPs) in chronic inflammatory diseases. *Mitochondrion.* 2018; 41:37–44. <https://doi.org/10.1016/j.mito.2017.12.001>
- Desbats MA, Lunardi G, Doimo M et al. Genetic bases and clinical manifestations of coenzyme Q10 (CoQ10) deficiency. *J Inherit Metabol Dis.* 2015; 38(1):145–156. <https://doi.org/10.1007/s10545-014-9749-9>
- Dhondup T, Qian Q. Electrolyte and acid-base disorders in chronic kidney disease and end-stage kidney failure. *Blood Purification.* 2017; 43(1–3):179–188. <https://doi.org/10.1159/000452725>
- Diomedes-Camassei F, Di Giandomenico S, Santorelli FM et al. COQ2 nephropathy: a newly described inherited mitochondrialopathy with primary renal involvement. *J Am Soc Nephrol.* 2007; 18(10):2773–2780. <https://doi.org/10.1681/asn.2006080833>
- Doimo M, Desbats MA, Cerqua C et al. Genetics of coenzyme Q10 deficiency. *Molec Syndromol.* 2014; 5(3–4):156–162. <https://doi.org/10.1159/000362826>
- Emma F, Montini G, Parikh SM, Salviati L. Mitochondrial dysfunction in inherited renal disease and acute kidney injury. *Nat Rev Nephrol.* 2016; 12(5):267–280. <https://doi.org/10.1038/nrneph.2015.214>
- Emma F, Salviati L. Mitochondrial cytopathies and the kidney. *Néphrologie Thérapeutique.* 2017; 13(S1):S23–S28. <https://doi.org/10.1016/j.nephro.2017.01.014>
- Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. *Biochim Biophys Acta.* 1995; 1271(1):195–204
- Ernster L, Forsmark P, Nordenbrand K. The mode of action of lipid-soluble antioxidants in biological membranes: relationship between the effects of ubiquinol and vitamin E as inhibitors of lipid peroxidation in submitochondrial particles. *Biofactors.* 1992; 3(4):241–248
- Ernster L, Forsmark-Andrée P. Ubiquinol: an endogenous antioxidant in aerobic organisms. *Clin Investig.* 1993; 71(S8):S60–65
- Fan L, Feng Y, Chen G-C et al. Effects of coenzyme Q10 supplementation on inflammatory markers: a systematic review and meta-analysis of randomized controlled trials. *Pharmacol Research.* 2017; 119:128–136. <https://doi.org/10.1016/j.phrs.2017.01.032>
- Finkel T. Signal transduction by reactive oxygen species. *J Cell Biol.* 2011; 194(1):7–15. <https://doi.org/10.1083/jcb.201102095>
- Frei B, Kim MC, Ames BN. Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations. *Proc Natl Acad Sci USA.* 1990; 87(12):4879–4883
- Galli F, Varga Z, Balla J et al. Vitamin E, lipid profile, and peroxidation in hemodialysis patients. *Kidney Int.* 2001; 59(S78):S148–S154. <https://doi.org/10.1046/j.1523-1755.2001.59780148.x>
- García-Corzo L, Luna-Sánchez M, Doerrier C et al. Ubiquinol-10 ameliorates mitochondrial encephalopathy associated with CoQ deficiency. *Biochim Biophys Acta: Molecular Basis of Disease.* 2014; 1842(7):893–901. <https://doi.org/10.1016/j.bbadis.2014.02.008>
- Gempel K, Topaloglu H, Talim B et al. The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. *Brain.* 2007; 130(8):2037–2044. <https://doi.org/10.1093/brain/awm054>
- Granata S, Dalla Gassa A, Tomei P et al. Mitochondria: a new therapeutic target in chronic kidney disease. *Nutr Metabol.* 2015; 12(1). <https://doi.org/10.1186/s12986-015-0044-z>
- Granata S, Zaza G, Simone S et al. Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. *BMC Genomics.* 2009; 10(1):388. <https://doi.org/10.1186/1471-2164-10-388>
- Grazioli S, Pugin J. Mitochondrial damage-associated molecular patterns: from inflammatory signaling to human diseases. *Frontiers Immunol.* 2018; 9. <https://doi.org/10.3389/fimmu.2018.00832>
- Gutierrez-Mariscal FM, Yubero-Serrano EM, Villalba JM, Lopez-Miranda J. Coenzyme Q10: from bench to clinic in aging diseases, a translational review. *Crit Rev Food Sci*

- Nutr. 2018; 16(1):1–18. <https://doi.org/10.1080/10408398.2018.1442316>
- Hall AM, Vilasi A, Garcia-Perez I et al. The urinary proteome and metabolome differ from normal in adults with mitochondrial disease. *Kidney Int.* 2015; 87(3):610–622. <https://doi.org/10.1038/ki.2014.297>
- Hargreaves IP. Ubiquinone: cholesterol's reclusive cousin. *Ann Clin Biochem.* 2003; 40(3):207–218. <https://doi.org/10.1258/000456303321610493>
- Hargreaves I, Mody N, Land J, Heales S. Blood mononuclear cell mitochondrial respiratory chain complex IV activity is decreased in multiple sclerosis patients: effects of  $\beta$ -interferon treatment. *J Clin Med.* 2018; 7(2):36. <https://doi.org/10.3390/jcm7020036>
- Hargreaves IP. Coenzyme Q10 as a therapy for mitochondrial disease. *Int J Biochem Cell Biol.* 2014; 49:105–111. <https://doi.org/10.1016/j.biocel.2014.01.020>
- Hargreaves IP, Al Shahrani M, Wainwright L, Heales SJR. Drug-induced mitochondrial toxicity. *Drug Safety.* 2016; 39(7):661–674. <https://doi.org/10.1007/s40264-016-0417-x>
- Heeringa SF, Chernin G, Chaki M et al. COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. *J Clin Invest.* 2011; 121(5):2013–2024. <https://doi.org/10.1172/jci45693>
- Huang S-Y, Chen Y-A, Chen S-A et al. Uremic toxins—novel arrhythmogenic factor in chronic kidney disease-related atrial fibrillation. *Acta Cardiol Sin.* 2016; 32(3):259–264. <https://doi.org/10.6515/acs20151116a>
- Ishikawa A, Kawarazaki H, Ando K et al. Renal preservation effect of ubiquinol, the reduced form of coenzyme Q10. *Clin Experiment Nephrol.* 2011; 15(1):30–33. <https://doi.org/10.1007/s10157-010-0350-8>
- Johansson P, Dahlström Ö, Dahlström U, Alehagen U. Improved health-related quality of life, and more days out of hospital with supplementation with selenium and coenzyme Q10 combined. Results from a double blind, placebo-controlled prospective study. *J Nutr Health Aging.* 2015; 19(9):870–877. <https://doi.org/10.1007/s12603-015-0509-9>
- Kalén A, Appelkvist EL, Dallner G. Age-related changes in the lipid compositions of rat and human tissues. *Lipids.* 1989; 24(7):579–584
- Lippa S, Colacicco L, Bondanini F et al. Plasma levels of coenzyme Q10, vitamin E and lipids in uremic patients on conservative therapy and hemodialysis treatment: some possible biochemical and clinical implications. *Clinica Chimica Acta.* 2000; 292(1–2):81–91. [https://doi.org/10.1016/s0009-8981\(99\)00204-1](https://doi.org/10.1016/s0009-8981(99)00204-1)
- Littarru GP, Tian L. Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. *Mol Biotechnol.* 2007; 37(1):31–37
- Littlefield N, Beckstrand RL, Luthy KE. Statins' effect on plasma levels of Coenzyme Q10 and improvement in myopathy with supplementation. *J Am Assoc Nurs Practit.* 2014; 26(2):85–90. <https://doi.org/10.1002/2327-6924.12046>
- Macunluoglu B, Atakan A, Ari E et al. Epicardial fat tissue thickness is correlated with diminished levels of co-enzyme Q10, a major antioxidant molecule among hemodialysis patients. *Clin Biochem.* 2014; 47(13–14):1231–1234. <https://doi.org/10.1016/j.clinbiochem.2014.05.057>
- Mantle D. Coenzyme Q10 and cardiovascular disease: an overview. *Br J Cardiol.* 2015. <https://doi.org/10.5837/bjc.2015.037>
- Marbois B, Gin P, Faull KF et al. Coq3 and Coq4 Define a polypeptide complex in yeast mitochondria for the biosynthesis of coenzyme Q. *J Biol Chem.* 2005; 280(21):20231–20238. <https://doi.org/10.1074/jbc.m501315200>
- Martinefski M, Samassa P, Buontempo F et al. Relative bioavailability of coenzyme Q10 formulation for paediatric individualized therapy. *J Pharmacy Pharmacol.* 2017; 69(5):567–573. <https://doi.org/10.1111/jphp.12613>
- Matsuzaki S, Szewda PA, Szewda LI, Humphries KM. Regulated production of free radicals by the mitochondrial electron transport chain: cardiac ischemic preconditioning. *Adv Drug Deliv Rev.* 2009; 61(14):1324–1331. <https://doi.org/10.1016/j.addr.2009.05.008>
- Meyer A, Laverny G, Bernardi L et al. Mitochondria: an organelle of bacterial origin controlling inflammation. *Frontiers Immunol.* 2018; 9. <https://doi.org/10.3389/fimmu.2018.00536>
- Miranda S, Foncea R, Guerrero J, Leighton F. Oxidative stress and upregulation of mitochondrial biogenesis genes in mitochondrial DNA-depleted HeLa cells. *Biochem Biophys Res Commun.* 1999; 258(1):44–49. <https://doi.org/10.1006/bbrc.1999.0580>
- Montini G, Malaventura C, Salviati L. Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. *N Engl J Med.* 2008; 358(26):2849–2850. <https://doi.org/10.1056/nejmc0800582>
- Mortensen SA, Rosenfeldt F, Kumar A et al. The effect of coenzyme q 10 on morbidity and mortality in chronic heart failure. *JACC: Heart Failure.* 2014; 2(6):641–649. <https://doi.org/10.1016/j.jchf.2014.06.008>
- Mutsaers HAM, Wilmer MJG, Reijnders D et al. Uremic toxins inhibit renal metabolic capacity through interference with glucuronidation and mitochondrial respiration. *Biochim Biophys Acta: Molecular Basis of Disease.* 2013; 1832(1):142–150. <https://doi.org/10.1016/j.bbadis.2012.09.006>
- Navas P, Villalba JM, de Cabo R. The importance of plasma membrane coenzyme Q in ageing and stress responses. *Mitochondrion.* 2007; 7:S34–S40. <https://doi.org/10.1016/j.mito.2007.02.010>
- Neergheen V, Chalasani A, Wainwright L et al. Coenzyme Q 10 in the treatment of mitochondrial disease. *J Inborn Errors Metabol Screening.* 2017; 5:2326409817707777. <https://doi.org/10.1177/2326409817707777>
- Oberg BP, McMennamin E, Lucas FLEE et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. *Kidney Int.* 2004; 65(3):1009–1016. <https://doi.org/10.1111/j.1523-1755.2004.00465.x>
- Owada S, Maeba T, Sugano Y et al. Spherical carbon adsorbent (AST-120) protects deterioration of renal function in chronic kidney disease rats through inhibition of reactive oxygen species production from mitochondria and reduction of serum lipid peroxidation. *Nephron Experiment Nephrol.* 2010; 115(4):e101–e111. <https://doi.org/10.1159/000313491>
- Picca A, Lezza A, Leeuwenburgh C et al. Fueling inflammation through mitochondrial dysfunction: mechanisms and molecular targets. *Int J Molec Sci.* 2017; 18(5):933. <https://doi.org/10.3390/ijms18050933>
- Public Health England. Chronic kidney disease prevalence model. 2014. <https://www.renalreg.org/wp-content/uploads/2014/10/CKD-prevalence-final.pdf> (accessed 28 February 2019)
- Qu H, Guo M, Chai H et al. Effects of coenzyme Q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials. *J Am Heart Assoc.* 2018; 7(19). <https://doi.org/10.1161/jaha.118.009835>
- Quinlan CL, Perevoshchikova IV, Hey-Mogensen M et al. Sites of reactive oxygen species generation by mitochondria oxidizing different substrates. *Redox Biol.* 2013; 1(1):304–312. <https://doi.org/10.1016/j.redox.2013.04.005>

- Quinzii C, Naini A, Salviati L et al. A mutation in para-hydroxybenzoate-polyphenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. *Am J Hum Genet.* 2006; 78(2):345–349. <https://doi.org/10.1086/500092>
- Rivara MB, Yeung CK, Robinson-Cohen C et al. Effect of coenzyme Q10 on biomarkers of oxidative stress and cardiac function in hemodialysis patients: the CoQ10 biomarker trial. *Am J Kidney Dis.* 2017; 69(3):389–399. <https://doi.org/10.1053/j.ajkd.2016.08.041>
- Romagnani P, Remuzzi G, Glasscock R et al. Chronic kidney disease. *Nat Rev Dis Primers.* 2017; 23(3):17088. <https://doi.org/10.1038/nrdp.2017.88>
- Romagnoli A, Oradei A, Destito C et al. Protective role in vivo of Coenzyme Q10 during reperfusion of ischemic limbs. *Molec Aspects Med.* 1994; 15(1):s177–s185. [https://doi.org/10.1016/0098-2997\(94\)90027-2](https://doi.org/10.1016/0098-2997(94)90027-2)
- Rötig A, Appelkvist E-L, Geromel V et al. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. *Lancet.* 2000; 356(9227):391–395. [https://doi.org/10.1016/s0140-6736\(00\)02531-9](https://doi.org/10.1016/s0140-6736(00)02531-9)
- Skarlovnik A, Janic M, Lunder M et al. Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study. *Med Sci Monit.* 2014; 20(6):2183–2188. <https://doi.org/10.12659/msm.890777>
- Salviati L, Sacconi S, Murer L et al. Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. *Neurol.* 2005; 65(4):606–608. <https://doi.org/10.1212/01.wnl.0000172859.55579.a7>
- Sarkar S, Malovic E, Harishchandra DS et al. Mitochondrial impairment in microglia amplifies NLRP3 inflammasome proinflammatory signaling in cell culture and animal models of Parkinson's disease. *NPJ Parkinson's Disease.* 2017; 17(3):30. <https://doi.org/10.1038/s41531-017-0032-2>
- Schmelzer C, Lindner I, Rimbach G et al. Functions of coenzyme Q10 in inflammation and gene expression. *Biofactors.* 2008; 32(1–4):179–183
- Singh RB, Kumar A, Niaz MA et al. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in patients with end-stage renal failure. *J Nutr Environmental Med.* 2003; 13(1):13–22. <https://doi.org/10.1080/1359084031000095002>
- Singh L, Singh G, Dinda AK. Understanding podocytopathy and its relevance to clinical nephrology. *Indian J Nephrol.* 2015; 25(1):1–7. <https://doi.org/10.4103/0971-4065.134531>
- Solin ML, Pitkanen S, Taanman JW, Holthofer H. Mitochondrial dysfunction in congenital nephrotic syndrome. *Lab Invest.* 2000; 80(8):1227–1232
- Stepien KM, Heaton R, Rankin S et al. Evidence of oxidative stress and secondary mitochondrial dysfunction in metabolic and non-metabolic disorders. *J Clin Med.* 2017; 6(7):71. <https://doi.org/10.3390/jcm6070071>
- Su M, Dhooopun A-R, Yuan Y et al. Mitochondrial dysfunction is an early event in aldosterone-induced podocyte injury. *Am J Physiol-Renal Physiol.* 2013; 305(4):F520–F531. <https://doi.org/10.1152/ajprenal.00570.2012>
- Takahashi T, Okamoto T, Kishi T. Characterization of NADPH dependent ubiquinone reductase activity in rat liver cytosol: effect of various factors on ubiquinone-reducing activity and discrimination from other quinone reductases. *J Biochem.* 1996; 119(2):256–63
- Tomasetti M, Allegra R, Solenghi MD, Littarru GP. Distribution of antioxidants among blood components and lipoproteins: significance of lipids/CoQ10 ratio as a possible marker of increased risk for atherosclerosis. *Biofactors.* 1999; 9(2–4):231–240
- Triolo L, Lippa S, Oradei A et al. Serum coenzyme Q10 in uremic patients on chronic hemodialysis. *Nephron.* 1994; 66(2):153–156. <https://doi.org/10.1159/000187793>
- Turunen M, Olsson J, Dallner G. Metabolism and function of coenzyme Q. *Biochimica et Biophysica Acta: Biomembranes.* 2004; 1660(1–2):171–199. <https://doi.org/10.1016/j.bbamem.2003.11.012>
- Villalba JM, Navas P. Plasma membrane redox system in the control of stress-induced apoptosis. *Antioxidants & Redox Signaling.* 2000; 2(2):213–230. <https://doi.org/10.1089/ars.2000.2.2-213>
- Weber C, Bysted A, Hlmer G. The coenzyme Q10 content of the average Danish diet. *Int J Vitam Nutr Res.* 1997; 67(2):123–129
- Weis M, Mortensen SA, Rassing MR et al. Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. *Mol Aspects Med.* 1994; 15S:s273–280
- Yeung CK, Billings FT, Claessens AJ et al. Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress. *BMC Nephrol.* 2015; 16(1):183. <https://doi.org/10.1186/s12882-015-0178-2>
- Yubero D, Montero R, Artuch R et al. Biochemical diagnosis of coenzyme Q10 deficiency. *molecular syndromology.* 2014; 5(3–4):147–155. <https://doi.org/10.1159/000362390>
- Yubero D, Montero R, Martín MA et al. Secondary coenzyme Q 10 deficiencies in oxidative phosphorylation (OXPHOS) and non-OXPHOS disorders. *Mitochondrion.* 2016; 30:51–58. <https://doi.org/10.1016/j.mito.2016.06.007>
- Yubero D, Montero R, Ramos M et al. Determination of urinary coenzyme Q 10 by HPLC with electrochemical detection: reference values for a paediatric population: determination of urinary coenzyme Q 10. *BioFactors.* 2015; 41(6):424–430. <https://doi.org/10.1002/biof.1242>
- Yubero D, Montero R, Santos-Ocaña C et al. Molecular diagnosis of coenzyme Q 10 deficiency: an update. *Expert Rev Molec Diagnost.* 2018; 18(6):491–498. <https://doi.org/10.1080/14737159.2018.1478290>
- Zahed N-S, Ghassami M, Nikbakht H. Effects of coenzyme Q10 supplementation on C-reactive protein and homocysteine as the inflammatory markers in hemodialysis patients: a randomized clinical trial. *J Nephrothol.* 2015; 5(1):38–43. <https://doi.org/10.15171/jnp.2016.07>

Have an idea for **JKC?**

☎ 020 7738 5454 ✉ [jkc@markallengroup.com](mailto:jkc@markallengroup.com) 🐦 @JKidneyCare